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Accepted 24 March 2014Aubipyc is an organogold(III) compound endowed with encouraging anti-proliferative proper-
ties in vitro that is being evaluated pre-clinically as a prospective anticancer agent. A classical
proteomic approach is exploited here to elucidate the mechanisms of its biological actions in
A2780human ovarian cancer cells. Based on 2-D gel electrophoresis separation and subsequent
mass spectrometry identification, a considerable number of differentially expressed proteins
were highlighted in A2780 cancer cells treated with Aubipyc. Bioinformatic analysis of the
groups of up-regulated and down-regulated proteins pointed out that Aubipyc primarily
perturbsmitochondrial processes and the glycolytic pathway. Notably, somemajor alterations
in the glycolytic pathway were validated throughWestern blot andmetabolic investigations.
Biological significance
This is the first proteomic analysis regarding Aubipyc cytotoxicity in A2780/S ovarian cancer
cell line. Aubipyc is a promising gold(III) compound which manifests an appreciable
cytotoxicity toward the cell line A2780, being able to overcome resistance to platinum. The
proteomic study revealed for Aubipyc different cellular alterations with respect to cisplatin
as well as to other gold compound such as auranofin. Remarkably, the bioinformatic
analysis of proteomic data pointed out that Aubipyc treatment affected, directly or
indirectly, several glycolytic enzymes. These data suggest a new mechanism of action for
this gold drug and might have an impact on the use of gold-based drug in cancer treatment.
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Fig. 1 – Chemical structure of Aubipyc.
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Metal-based agents, andmore specifically platinum drugs, play
a major role in current chemotherapeutic regimens for cancer
treatment [1]. Nonetheless, the clinical use of platinumdrugs is
still heavily limited by a high systemic toxicity and by the
frequent occurrence of intrinsic or acquired resistance [2]. This
triggered the search of other families of anticancer drugs based
on metals different from platinum, e.g. ruthenium, tin and
copper [3]. Nowadays, gold compounds offer an effective and
innovative alternative to platinum drugs and are therefore
intensively investigated [4]. Interest in gold compounds is also
fuelled by the observation that they usually manifest a very
different pharmacological profile compared to established
anticancer platinum drugs implying the occurrence of original
and innovative modes of action and the chance to overcome
platinum resistance [5,6]. Hence, over the last two decades,
several promising families of Au-based drug candidates, with
the gold center in the oxidation state +3 or +1, featuring diverse
structural motifs, were prepared, characterized and their
biological and pharmacological profiles initially assessed [7,8].
Relevant examples are offered by a few classical mononuclear
gold(III) complexes [9] such as gold(III) dithiocarbamates [10]
and gold(III) porphyries [11]; by some organogold(III) com-
pounds [12,13]; a few binuclear gold(III) complexes [14]; various
neutral, two-coordinate gold(I) complexes [15], inspired to
auranofin; a number of lyophilise cationic gold(I) complexes
such as [Au(dope)2]+, and others.
Compounds were mainly driven by their chemical analogy
with platinum(II)-based drugs [6]. It was postulated that the
biological effects of gold(III) compounds might be a conse-
quence of direct DNA damage as for cisplatin and its analogs.
However, in contrast to general expectations, a number of
subsequent studies suggested that gold(III) compounds exert
their cytotoxicity and antiproliferative effects mainly through
DNA independent mechanisms [16]. Notably, it has been
shown that these gold(III) compounds are able to trigger
apoptosis by a direct mitochondrial damage [1,12,17,18]. Also,
there are suggestions that a few peculiar proteins such as
thioredoxin reductase, the proteasome or the nuclear factor
kb (NF-kb) systemmay constitute major targets for these gold
compounds [1,18–20].
Aubipyc is a promising gold(III) compound that was charac-
terized chemically and biologically through a few recent studies
[21,22]. It consists of a square planar gold(III) center receiving
three donors – i.e. C, N, N – from the tridentate bipyridyl ligand
while the fourth coordination position is occupied by a
hydroxide group (Fig. 1); the latter is the preferential site for
ligand replacement reaction and for protein biding. Aubipyc is
acceptably stable under physiological conditions even in the
presence of reducing agents. Previous studies revealed that
Aubipyc manifests an appreciable cytotoxicity toward the
human ovarian cancer cell line A2780, being able to overcome
resistance to platinum. Moreover, it was found that Aubipyc
induces apoptotic cell death [21]. Since this gold compound is a
strong inhibitor of thioredoxin reductase, it was hypothesized
that cell death proceeds through apoptosis possibly as a
consequence of a direct mitochondrial damage [23]. However,
details of the molecular mechanism leading to mitochondrialdamage and consequent induction of apoptosis remain unex-
plored and warrant further studies.
Here we have adopted a proteomic approach to better
characterize themechanism of action of Aubipyc. Proteomics is
today a very powerful investigation tool of cellular processes
providing detailed and direct insight into the fine alterations in
cell homeostasis induced by exposure to drugs and xenobiotics.
Such alterations occurring at the level of several intracellular
signaling and metabolic pathways may tell us which parts of
the complex cellular machinery are mainly affected by treat-
ment, also suggesting which parts are the most probable
biomolecular targets for a specific compound. Previous studies
well documented the application of proteomic approaches to
the study of the mechanism of various anticancer metal-based
drugs [24]. Studies on platinum compounds revealed cellular
responses induced by cisplatin treatment and alsodisclosed the
molecular basis for platinum resistance [25,26]. On the other
hand, a number of studies on the proteomic effects of selected
gold compounds illustrated the complex responses elicited in
cancer cells, highlighting the role of specific defense systems.
Some interesting hypotheses were made concerning the likely
antiproliferative mechanisms of some gold compounds.
Relevant changes in the expression of a number of proteins
engaged in redox metabolism, stress response, in mitochon-
drial functions as well as in apoptosis pathways were
detected [11,27]. In previous works we obtained proteomic
results for the gold(III) compound Auoxo6 and Auranofin on
A2780 cell line, either sensitive (A2780/S) or resistance
(A2780/R) to cisplatin. Concerning the A2780/S, the results
pointed out that the mode of action of Auoxo6 is strictly
related to that of auranofin. Both gold compounds trigger
caspase 3 activation and apoptosis and the affected proteins
are involved in cell redox homeostasis and stress response
[28]. Conversely, in the A2780/R cell line, Auranofin affected
the expression of proteasome apparatus proteins whereas
Auoxo6 modified the expression of proteins related to mRNA
trafficking and stability [29]. More recently, we performed a
proteomic study on two additional gold compounds, Au2phen
and Aul12 in A2780/S cells. The obtained results were
basically in line with those of Auoxo6 and Auranofin in
A2780/S cells. We observed few protein expression varia-
tions. Moreover, both compounds affected proteins involved
in protein synthesis, mRNA splicing and proteins involved in
proteasome-mediated protein degradation [30]. However, in
all these studies, no underlyingmechanism or pathway could
be clearly identified.
105J O U R N A L O F P R O T E O M I C S 1 0 3 ( 2 0 1 4 ) 1 0 3 – 1 2 0The aim of the present study was to characterize the
molecular basis of Aubipyc cytotoxicity in human ovarian
cancer cell line A2780/S. The proteome of treated cells was
examined with respect to that of untreated cells, by
two-dimensional electrophoresis coupled with mass spec-
trometry. We identified 87 differentially expressed proteins.
Among them, 29 proteins were up-regulated upon Aubipyc
exposure. Most of these proteins are involved in cellular
processes such as stress response, protein synthesis and
cytoskeleton and cell structure. Fifty-eight proteins were
down-regulated. Most of these proteins belong to glucose
metabolism, stress response and cell redox homeostasis.
The alteration on glucose metabolism, in particular of
glycolysis, was confirmed by Western blot, bioinformatic
analysis and metabolic investigations, such as glucose
consuming and the effect of extra pyruvate addition in
culture medium on antiproliferative activity of Aubipyc
against A2780/S cell line. These data indicate that Aubipyc
affects glycolytic pathway. This work therefore offers novel
insights, from the prospective of themetabolic response, into
the cytotoxic effects caused by Aubipyc-induced damage.2. Material and methods
2.1. Materials
RPMI 1640 cell culture medium, fetal calf serum (FCS), and
phosphate-buffered saline were obtained from Celbio (Milan,
Italy); sulforhodamine B (SRB) and cisplatin were obtained
from Sigma (Milan, Italy). All chemicals were purchased from
Sigma Aldrich (Italy), unless mentioned otherwise.
2.2. Cell lines and culture conditions
The human ovarian carcinoma cell line sensitive to cisplatin
(A2780/S) was used for cytotoxicity and proteomic studies.
Cells were maintained in RPMI1640 medium supplemented
with 10% of FCS and antibiotics at 37 °C in a 5% CO2
atmosphere and sub-cultured twice weekly.
2.3. Cell growth inhibition studies
The cytotoxic activity of Aubipyc was evaluated against the
A2780/S cell line according to the procedure described by
Skehan et al. [31]. Briefly, exponentially growing cells were
seeded in 96-well microplates for 24 h prior to the addition of
Aubipyc. After 24 h, the medium was removed and replaced
with fresh medium containing concentrations of Aubipyc
ranging from 0.003 to 100 μM. Two different times of
exposure to Aubipyc, 24 and 72 h, were used. For comparison
purposes the cytotoxicity of cisplatinwas evaluated in the same
experimental conditions. Then the cells were fixed with
trichloroacetic acid and then stained with sulforhodamine B
(SRB) solution, rinsed with 0.1% acetic acid and air-dried. At the
end of the staining period, SRBwas dissolved in 10 mMTris–HCl
solution (pH 10.5). Optical density was read in a microplate
reader interfaced with the software Microplate Manager/PV
version 4.0 (Bio-Rad Laboratories, Milan, Italy) at 540 nm. The
IC50 drug concentration resulting in a 50% reduction in the netprotein content (as measured by SRB staining) in drug-treated
cells as compared with untreated control cells was determined.
The IC50 drug concentration was also evaluated in medium
supplemented with 1 mM pyruvate. The reported IC50 data
represent the mean of at least three independent experiments.
2.4. Trypan blue vital dye exclusion assay
To evaluate the viability of cells to be used in the proteomic
studies, a time course at 24, 48 and 72 h drug exposures with
3.1 μM of Aubipyc (equal to 72-h-exposure IC50 value), was
performed by trypan blue vital dye exclusion assay. Briefly,
200 μL of trypsinized and re-suspended cells were mixed with
200 μL of 0.4% solution of trypan blue dye (Sigma-Aldrich) for
5 min. Numbers of total cells, live cells and dead cells, were
immediately counted using a Neubauer micro-chamber (Brand
GmbH,Wertheim, Germany) with a lightmicroscope. All counts
were done in duplicates of each sample. The reported data
represent the mean of three independent experiments.
2.5. Sample preparation and 2-D gel electrophoresis
A2780/S cells were seeded in tissue-culture plates at
5 × 104 cells/mL (total volume 30 mL) and incubated over-
night, then exposed to the concentration of the Aubipyc
equal to 72-h-exposure IC50 values for 24 h (3.1 μM). Aubipyc
stock solution was prepared in dimethyl sulfoxide, then
A2780/S control cells were treated with an equal concentra-
tion of DMSO. At the end of incubation the cells were
washed with phosphate-buffered saline and then scraped
in RIPA buffer (50 mM Tris–HCl pH 7.0, 1% (v/v) NP-40,
150 mM NaCl, 2 mM ethylene glycol bis(2-aminoethyl
ether)tetra-acetic acid, 100 mM NaF) containing a human
protease inhibitor cocktail (Sigma). The cells were sonicated
(15 s) and protein extracts were clarified by centrifugation
at 8000 g, 4 °C for 15 min. Proteinswere precipitated following a
chloroform/methanol protocol [32] and the protein pellets
were resolved in a buffer containing 8 M urea, 4% (w/v)
3-cholamidopropyl dimethylammonium-1-propane sulfonate
(CHAPS), 65 mM dithioerythritol (DTE). Protein concentration
was determined by the standard Bradford method (Bio-Rad).
Isoelectric focusing (IEF) was carried out on nonlinear wide-
range immobilized pH gradient (pH 3–10; 18-cm-long IPG strip;
Bio-Rad) and achieved using an Ettan IPGphor™ system (GE
Healthcare). Protein sample (700 μg) was cup-loaded near the
anode in the Ettan IPGphor Cup Loading Manifold™ (GE
Healthcare) after the rehydration of the IPG strips with 350 μL
of rehydration solution (8 M urea, 2% (w/v) CHAPS, 0.5% (w/v)
DTE) supplemented with 0.5% (v/v) carrier ampholyte (Bio-Rad)
and a trace of bromophenol blue, overnight at room tempera-
ture. The stripswere focused at 16 °C according to the following
electrical conditions: 200 V for 1 h, 300 V for 1 h, from 300 to
3500 V in 30 min, 3500 V for 4 h, 5000 for 2 h, from 5000 to
8000 V in 30 min, and 8000 V until a total of 100,000 V/h was
reached, with a limiting current of 50 μA/strip. After focusing,
stripswere equilibrated in 6 Murea, 2% (w/v) SDS, 2% (w/v) DTE,
30% (v/v) glycerol and 0.05 M Tris–HCl pH 6.8 for 10 min and,
subsequently, for 10 min in the same urea/SDS/Tris–HCl
buffer solution where DTE was substituted with 2.5% (w/v)
iodoacetamide (IA). The equilibrated strips were placed on
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20 cm × 1.5 mm) and embedded in 0.5% (w/v) heated
low-melting agarose in SDS electrophoresis running buffer
(25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS, pH 8.3). The
methylenebisacrylamidewas the cross-linker used in the 9–16%
gradient. SDS-PAGE was performed in a PROTEAN II xi cell gel
electrophoresis unit (Bio-Rad) at 10 °C and at 40 mA/gel
constant current, until the dye front reached the bottom of the
gel, according to Hochstrasser et al., [33]. Gelswere stainedwith
colloidal Coomassie blue silver [34].
2.6. Image analysis and statistics
Three independent Aubipyc treatments were performed
(biological replicates) and for each sample two 2-DE gels
were carried out (technical replicates), so that 12 gels in total
were analyzed (6 gels for both A2780/S Aubipyc-treated and
control cells). Colloidal Coomassie blue silver-stained gels
were digitized using the Epson expression 1680 PRO scanner.
The gel images were saved with a resolution of 300 dpi and as
16-bit TIFF format. Image analysis was carried out using the
Progenesis SameSpots software version 4.0 (Nonlinear Dy-
namics, UK) which allows spot detection, background sub-
traction and protein spot volume quantification. The gel
image showing the highest number of spots and the best
protein pattern was chosen as the reference image and its
spots were thenmatched across all gels. This reference image
was used to quantify and normalize the spot volumes. The spot
volumes were normalized in each gel as a relative volume
(volume percentage), by dividing the raw quantity of each spot
by the total quantity of all the spots included in the reference
gel. Statistical analysiswas performedusing default parameters
of the Progenesis SameSpots Statmodule. The log10-normalized
spot volumewas used for the analysis as the log transformation
improves normality [35]. The univariate data analysis was
performed as one-way ANOVA (p < 0.05) on each spot individ-
ually. Then, a multivariate statistics was applied including a
false discovery rate-corrected p-value (q-value) and Principal
Component Analysis (PCA). Moreover, we performed a power
analysis to asses the number of sample replicates that need
to be analyzed in order to confidently discover differentially
expressed proteins. The accepted power threshold is ≥0.8 [36].
We considered differentially expressed spots those having a
q-value ≤0.05 and a power ≥0.8. These spots were subjected to
mass spectrometry analysis.
2.7. Mass spectrometry analysis
Electrophoretic spots were manually excised, destained, and
acetonitrile dehydrated. A trypsin solution (0.25 mg/mL) in
50 mM ammonium bicarbonate was added for in-gel protein
digestion by overnight incubation at 37 °C. Solutions contain-
ing digested peptides were recovered and 20 μL of 1% TFA 50%
ACN was added to each spot and sonicated for 10 min to
maximize peptide recovery. At the end, all recovered peptide
solutions were combined and concentrated for each spot
separately. From each protein digest 0.75 μL was spotted onto
the MALDI target and allowed to air dry at room temperature.
Then, 0.75 μL of matrix solution (saturated solution of
α-cyano-4-hydroxycinnamic acid in 50% (v/v) acetonitrileand 0.5% (v/v) TFA) was applied to the sample and crystallized
by air drying at room temperature for 5 min. Protein identi-
fication was carried out by peptide mass fingerprinting (PMF)
on an Ultraflex III MALDI-TOF/TOFmass spectrometer (Bruker
Daltonics) equipped with a 200 Hz smartbeam™ I laser. MS
analysis was performed in the positive reflector mode
according to defined parameters, as follows: 80 ns of delay;
ion source 1: 25 kV; ion source 2: 21.75 kV; lens voltage:
9.50 kV; reflector voltage: 26.30 kV; and reflector 2 voltage:
14.00 kV. The applied laser wavelength and frequency were
353 nm and 100 Hz, respectively, and the percentage was set
to 46%. Final mass spectra were produced by averaging 1500
laser shots targeting five different positions within the spot.
Spectra were acquired automatically and the Flex Analysis
software version 3.0 (Bruker) was used for their analysis and for
the assignment of the peaks. The applied software generated a
list of peaks up to 200, using a signal-to-noise ratio of 3 as
threshold for peak acceptance. Recorded spectra were calibrat-
ed using, as an internal standard, peptides arising from trypsin
auto-proteolysis. The mass lists were filtered for contaminant
removal: mass matrix-related ions, trypsin auto-lysis and
keratinpeaks. Protein identification by PeptideMass Fingerprint
search was established using MASCOT search engine version
2.1 (Matrix Science, London, UK, http://www.matrixscience.
com) through the UniProtKB database (http://www.uniprot.
org/). Taxonomy was limited to Homo sapiens, a mass tolerance
of 100 ppm was allowed, and the number of accepted missed
cleavage sites was set to one. Alkylation of cysteine by
carbamidomethylation was considered a fixed modification,
while oxidation of methionine was considered as a possible
modification. The criteria used to accept identifications includ-
ed the extent of sequence coverage, the number of matched
peptides, and a probabilistic score at p < 0.05.
2.8. Western blot analysis
A2780/S cells were treated for 24 and 48 h with Aubipyc
concentration corresponding to its 72-h-exposure IC50 dose
(3.1 μM). Protein preparationwas the same as those of the 2-D
experiments. Protein samples (30 μg) were separated on 4–
16% gradient SDS-PAGE precast gels (Biorad) and transferred
onto a PVDF membrane (Millipore). The relative amount of the
GAPDH, PGK1, ENO1 and PKM was assessed with appropriate
monoclonal antibodies (Santa Cruz Biotechnology). Accord-
ing to datasheets, all antibodies were employed with a 1:1000
dilution in 2% milk. After incubation with horseradish
peroxidase (HRP)-conjugated anti-mouse IgG (1:2000)
(Amersham Biosciences), immune complexes were detected
with the enhanced chemiluminescence (ECL) detection
system (Amersham Biosciences). The membranes were
exposed to autoradiographic films (HyperfilmMP; Amersham
Biosciences) for 1–30 min. For quantification, blots were
subjected to densitometric analysis using Quantity One
Software (Bio-Rad). The intensity of the immunostained
bands was normalized with the total protein intensities
measured by Coomassie brilliant blue R-250 from the same
blot. Statistical analysis, of three independent experiments,
was performed by two-tailed non-paired Student's-t-test
using Graphpad Prism 4. A p-value < 0.05 was considered
statistically significant.
Table 1 – Antiproliferative activity of Aubipyc and
cisplatin against A2780/S ovarian carcinoma human cell
line, sensitive to cisplatin.
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A2780/S cells were treated for 48 h with Aubipyc concentration
corresponding to its 72-h-exposure IC50 dose (3.1 μM). One
milliliter of medium supernatant was harvested immediately
after the addition of Aubipyc (time 0) and then after 6, 12, 24,
48 h. Glucose concentration wasmeasured using commercially
kit based on the glucose oxidase/peroxidase enzymic procedure
(K-GLUC from Meganzyme). Experiments were performed in
triplicate. A two-tailed non-paired Student's-t-test was per-
formed using Graphpad Prism 4. A p-value < 0.05 was consid-
ered statistically significant.
2.10. Bioinformatic functional analysis
To identify statistically over-represented (enriched) Gene Ontol-
ogy terms among the differentially expressed proteins identified
by MS analysis, we used David Bioinformatics Resource (version
6.7) (Database for Annotation, Visualization and Integrated
Discovery; http://david.abcc.ncifcrf.gov/). The differentially
expressed proteins identified by MS were divided in two lists:
one containing theup-regulatedproteins andone containing the
down regulated proteins. These lists were compiled reporting
UniProtKB accession number. Fisher's exact test was used to
check for significant over-representation (p < 0.05) of GO
terms in the submitted dataset against theH. sapiens genome.
Furthermore Benjamini multiple testing was performed to
globally correct the p-value controlling family-wide false
discovery rate (p-value ≤ 0.1).
To perform network analysis we used the free-web portal
BioProfiling.de (http://www.BioProfiling.de). It provides a com-
mon interface for the collection of recently developed tools [37];
description and details of the tools can be found in original
publications [38]. The gene/protein list is profiledwith respect to
themost information available regarding gene function, protein
interactions, pathway relationships, in silico predicted
microRNA to gene associations, as well as, information
collected by text mining. The network analysis used has been
freely available web-based tool for the interpretation of
experimentally derived protein lists in the context of a global
PPI network. We uploaded a dataset containing the Uniprot
Accession of all the identified proteins. The significantly
enriched PPI networks have been determined with the default
parameter settings. PPI spider employs statistical methodology
inwhich the p-value is adjusted formultiple testing (Bonferroni
correction). The statistical significance of the inferred model is
estimated based on the distribution of the model size for a
random protein list. Statistical significance of the model is
computed by a Monte Carlo simulation procedure [37,38].
Cytoscape software (http://www.cytoscape.org/) was used for
visualizing the obtained molecular interaction networks [39].A2780/S IC50 (μM) ± ES
24 h 72 h
Aubipyc 10.73 ± 1.22 3.10 ± 0.10
n 3 3
Cisplatin 34.15 ± 0.17 2.17 ± 0.23
n 3 3
n, number of experiments; ES, standard error.3. Results
3.1. Cytotoxic effects of Aubipyc
The anti-proliferative properties of Aubipyc was measured in
A2780/S cell line and compared with that of cisplatin as
reported in the Materials and methods section. The IC50values, observed after exposure to both Aubipyc and cisplatin,
are reported in Table 1. After 24 h of exposure to Aubipyc, IC50
value was 10.73 μM whereas that of cisplatin was about
three-times higher (i.e. 34.15 μM). After 72 h of exposure to
Aubipyc substantial cytotoxic activity was observed. IC50 value
of Aubipyc fell in the low μM range and it was similar to IC50
obtained for cisplatin. These IC50 values closely matched those
recently determined on 36 different human tumor cell lines in
Oncotest [40]. Aubipyc turned out to be less potent than other
gold compounds such as Auoxo6 and Au2phen. In fact, Aubipyc
was only moderately effective in the Oncotest panel but it was
qualified as one of the most active gold(III) complexes on the
A2780 line. Remarkably, this compound is able to overcome
resistance to cisplatin [21].
3.2. Proteomic results and statistical analysis
To investigate the cytotoxic mechanism of Aubipyc, the
protein expression modifications induced by gold treatment
in A2780/S cells were analyzed with respect to untreated cells
by 2-DE based proteomics. A2780/S cells were treated, for
24 h, with Aubipyc at a concentration corresponding to its
72-h-exposure IC50 dose (3.1 μM) in order to reduce the cell
death and render a proteomic study well feasible. Indeed, a
time course at 24, 48 and 72 h drug exposures with 3.1 μM of
Aubipyc, by using trypan blue vital dye exclusion assay,
showed that after 24 h of exposure, the percentage of cell
growth inhibition compared to the control was 13.4% and the
viability of the adherent cells was 86.0%. After 48 h and 72 h
of drug exposure, the cell growth inhibition was 34.5 and
49.3%, respectively, and the viability of the adherent cells was
86.5 and 85.8%, respectively (Supplementary Table S1). After
Aubipyc treatment, cellular protein extracts were prepared
and separated by 2-D gel electrophoresis as reported in the
‘Material and methods’ section and the resulting 2-DE gels
were colloidal Coomassie blue silver-stained. To obtain
statistically significant results, we performed three indepen-
dent experiments for both Aubipyc-treated and -untreated
cells. To minimize gel-to-gel variation, 2-DE was performed
twice for each biological replicate so that, 6 gels were
analyzed for both Aubipyc-treated and control cells. In Fig. 2
representative 2-DE gels of control (A) and Aubipyc-treated
A2780/S cells (B) are shown. The 2-DE gel images were
analyzed by Progenesis SameSpots software 4.0 (Nonlinear
Dynamics, UK) using default parameters. After automatic
spot detection an average of about 1800 protein spots was
detected in each gel. The computational 2-DE gel image
Fig. 2 – Representative colloidal Coomassie blue silver-stained 2-DE gel images for A2780/S control cells (A) and for
Aubipyc-treated A2780/S cells (B). Whole-cellular proteins (700 μg) were separated on IPG strips with a pH gradient of 3–10
nonlinear, followed by separation on 9–16% linear gradient SDS-PAGE. Black circles and numbers indicate spots that were
statistically differentially expressed in Aubipyc-treated A2780/S respect to control cells. (C) Principal Components Analysis
(PCA) performed by Progenesis SameSpots 4.0 software (Nonlinear Dynamic, UK).
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(ANOVA p-value ≤ 0.05). In addition to univariate analysis
(ANOVA-test), multivariate analyses (q-value, PCA and power
analysis) were performed to explore categories of differential
protein expression. To reduce the expected level of false
positive we performed a statistical analysis on the ANOVA
p-values, by applying the false discovery rate correctionmethod
known as q-value [41]. A statistically significant q-value (≤0.05)
was found for 95 protein spots. To obtain an overview of the
proteomic data for overall trends inAubipyc-treated and control
cells amultivariate analysis by PCAwas performed. Gelswere
grouped according to the variance of their protein spot
expression. The PCA biplot, shown in Fig. 2C, reveals two
distinct expression profile groups corresponding to: i)
Aubipyc-treated A2780/S cells and ii) control cells. In the
PCA plot each point describes the collective expression
profiles of one sample and plot demonstrates consistent
reproducibility between the six replicate sampleswithin each
group (treated and untreated cells). Moreover, we calculated
the power of our statistical anal; [42]. In our experiments, we
achieved a target power of 87% confirming that the number of
sample replicates used was appropriate. We considered as
statistically differentially expressed the protein spots with a
q-value ≤ 0.05 and a power ≥0.8. Among the 95 differentially
expressed protein spots, 35 factors were up-regulated where-
as 60 were down-regulated in Aubipyc-treated cells withrespect to control cells. Such protein spots are highlighted
with circles and numbers in the representative gels shown in
Fig. 2A and B. These spots were subjected tomass spectrometry
analysis and 87 proteins were successfully identified: 29
up-regulated and 58 down-regulated after Aubipyc-treatment.
The results of mass spectrometry identification are reported in
Table 2, together with the corresponding spot numbers, score
and coverage values of MALDI-TOF analysis, fold change in
expression level and q-value. The experimental isoelectric point
(pI) and molecular mass (Mr) values of the identified proteins
mostly matched with those theoretically predicted from the
genome sequence. More than one protein spot was found to
correspond to the same protein, consistently with the presence
of different post-translationally modified forms of the same
proteins (Table 2). For example, we identified three spots as
GAPDH, one of which (spot 66) was of higher molecular mass
(36 kDa) and two of which (spots 44 and 59) were of lower
molecular mass (35 kDa and 24 kDa respectively). This may be
tentatively explained with the presence of post-translationally
modified forms of GAPDH in agreement with several 2-DE-
based studies which report the identification of this protein in
spots with different position on 2-D gels [43,44]. In some
instances, the same protein was identified in spots that
displayed a strong discrepancy between the observed position
on 2-DE gels and the normalMr, with a shift toward lowermass
(e.g. spots 33, 35, 38, 53) suggesting the presence of protein
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interest that differentially expressed protein spots were found
to be products of the same gene. In particular, for some spots, in
Aubipyc treated cells, we observed a decrease of the full length
protein amount with a concomitant increase of protein forms
with lower Mr, suggesting the presence of protein fragments.
For example, in treated cells, we identified four spots as
HSP704L, of which two of higher molecular mass (about
94 kDa, matching with the predicted Mr) were decreased,
whereas two of lower molecular mass (about 88 kDa) were
increased. Hsc71, T-complex protein 1 subunit alpha and GMPS
showed the same trend (Table 2, Fig. 2).
The final number of unique identified proteins was 26 for
the up-regulated proteins and 45 for those down-regulated.
All the identified proteins were classified into functional
categories on the basis of the Gene Ontology (GO) terms
related to their major biological functions using UniprotKB
database (http://www.uniprot.org/). In Fig. 3 we reported the
percentage of both up-regulated and down-regulated pro-
teins, annotated in each functional category. Most of the
up-regulated proteins belong to the functional classes of
stress response and chaperones (41.5%), protein synthesis
(17.2%), metabolism (13.8%) and cytoskeleton and cell struc-
ture (13.8%). The remaining identified proteins are shared out
among cell cycle and apoptosis (3.4%), cell redox homeostasis
(3.4%) and DNA replication and repair (6.9%). Concerning the
down-regulated proteins, the most represented classes were
those of metabolism (31%), protein synthesis (22.4%), stress
response and chaperones (19%) and cell redox homeostasis
(10.3%). The smaller functional classes are transport (7%), cell
cycle and apoptosis (5.2%), signal transduction (3.4%) and
cytoskeleton and cell structure (1.7%).
3.3. Functional GO terms and pathway enrichment analysis
To better understand biological meaning behind the list of
proteins obtained after the Aubipyc treatment we used the
web-accessible program DAVID (Database Annotation Visuali-
zation and Integrated Discovery version 6.7 http://david.abcc.
ncifcrf.gov/home.jsp) [45,46] and relative functional annotation
tools. DAVID provides information whether any GO categories
were statistically enriched by a gene/protein list. To this aimwe
uploaded two different lists containing the: i) up-regulated
protein and ii) down-regulated protein, respectively. A Fisher's
enrichment analysiswas carried out by comparing the frequen-
cies of the annotation terms in each protein subset with that of
the whole list. Fig. 4 displays the obtained GO Biological Process
(BP) terms statistically over-represented (p-value ≤ 0.1 after
Benjamini correction). Detailed composition and statistical
parameters were reported in Table S2. Most of the top score
biological processes, enriched by the 29 up-regulated proteins
(Fig. 4A), included ontologies involved in protein synthesis and
folding: ‘protein folding’ (GO:0006457), ‘protein metabolic
process’ (GO:0019538) and ‘cellular protein metabolic
process’(GO:0044267). In these GO BP terms we found the
proteins corresponding to the functional category ‘stress
response and chaperones’ reported in Table 2. We found
different subunits of T-complex protein 1. The TCP-1
chaperonin family known as ‘eukaryotic cytosolic chaperonin
containing TCP-1 (CCT)’ has a critical function in the folding ofmany proteins, including the cytoskeletal components actin
and tubulin [47]. We also found different members of the heat
shock family such as, HSP60 mitochondrial, Hsc71 and Heat
shock 70 kDa protein 4L. Concerning the enriched GO terms
associated with protein metabolism we found two elongation
factors such as Elongation factor Tu mitochondrial and
Elongation factor 2, the protein pre-mRNA-processing factor
19 involved in spliceosome assembly, the RuvB-like 1 important
for DNA repair and the dihydrolipoyl dehydrogenase mitochon-
drial associated with protein folding. Several proteins are shared
between different GO terms all related to cellular metabolism
(GO:0009987, GO:0044237, GO:0044238, GO:0008152). These
terms contained all the proteins found in the enriched BP
terms described above together with the mitochondrial
NADH-ubiquinone oxidoreductase 75 kDa subunit involved
in cellular respiration and two proteins involved in purine
metabolism such as c-1-tetrahydrofolate synthase and GMP
synthetase. Proteins involved in mRNA processing such as
heterogeneous nuclear ribonucleoprotein H, heterogeneous
nuclear ribonucleoprotein K and heterogeneous nuclear
ribonucleoprotein Q, are also included. Three up-regulated
proteins are involved in cytoskeleton rearrangement such as
ezrin, vinculin and actin-related protein 3. This finding is in
agreement with the data on the TCP-1 chaperonin family that
acts primary on cytoskeleton remodeling.
The top score GO BP terms enriched by the down-regulated
protein list (Fig. 4B and Table S2) included ontologies associated
with metabolism and energy production such as ‘metabolic
process’ (GO:0008152), ‘cellularmetabolic process’ (GO:0044237),
‘generation of precursor metabolites and energy’ (GO:0006091)
and ‘glycolysis’ (GO:0006096). Several isoforms of glycolytic
enzymes such as glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), alpha enolase (ENO1), phosphoglycerate kinase 1
(PGK1) and pyruvate kinase isozymes M1/M2 (PKM) were
included in these categories. Also, mitochondrial proteins
involved in energy production (ATP synthase subunit alpha,
enoyl-CoA hydratase, and ketoacid coenzyme A transferase 1)
were present. Interestingly, we found enriched the BP term ‘cell
redox homeostasis’ (GO:0045454, includingmitochondrial SCO2
homolog peroxiredoxin-6 protein disulfide-isomerase A3 and
the cytoplasmic thioredoxin reductase 1), suggesting a
drug-induced reduction of antioxidant potential of the cells.
In parallel to this GO enrichment analysis, we also searched
for statistically enriched pathways through DAVID software.
Using the list of the down-regulated proteins, we found
over-represented the ‘glycolysis pathway’ with both Biocarta
and KEGG pathways (p-value <0.1 after Benjamini correction).
This pathway enrichment confirmed the GO BP term observa-
tions achieved with the down-regulated proteins, where the
term ‘glycolysis’ were over-represented (Fig. 4B and Table S2).
The proteins associated with the term ‘glycolysis’, are GAPDH,
PGK1, ENO1 and PKM (Fig. 5).
3.4. Protein validation by Western blot
Western blot analysis was used to validate the expression
changes of the glycolytic enzymes GAPDH, PGK1, ENO1 and
PKM in A2780/S treated for 24 h with 3.1 μM Aubipyc. A
representative immunoblot was shown in Fig. 6A whereas the
complete blot is provided in Fig. S1. For each tested protein the
Table 2 – Differentially expressed protein spots identified by MALDI TOF mass spectrometry analysis.
Spot
no. a
Protein description ACb Gene
name
Subcellular
localization
Mascot search results Fold change f
(Aubipyc vs
Control)
ANOVA
p-valueg
q-valueh
Score c Matched
Pept. d
Seq.
coverage
(%) e
Stress response and chaperones
2 Heat shock 70 kDa protein 4L O95757 HSPA4L Cytosol 220 23/33 30 −1.6 0.038 <0.05
3 Heat shock 70 kDa protein 4L O95757 HSPA4L Cytosol 160 18/32 30 −1.8 0.002 <0.02
5 Heat shock 70 kDa protein 4L O95757 HSPA4L Cytosol 382 42/56 54 2 0.036 <0.05
86 Heat shock 70 kDa protein 4L O95757 HSPA4L Cytosol 206 21/29 28 1.8 0.029 <0.05
13 Stress-70 protein, mitochondrial P38646 HSPA9 mitochondrion 376 50/86 63 1.9 0.029 <0.05
14 Stress-70 protein, mitochondria P38646 HSPA9 Mitochondrion 324 34/52 54 1.7 0.021 <0.05
12 Heat shock cognate 71 kDa protein P11142 HSPA8 Cytosol 241 31/69 55 −2.9 0.003 <0.02
15 Heat shock cognate 71 kDa protein P11142 HSPA8 Cytosol 233 32/71 56 2.2 0.033 <0.05
56 Heat shock cognate 71 kDa protein
(N-fragment)
P11142 HSPA8 Cytosol 159 22/46 30 −2 0.018 <0.05
18 T-complex protein 1 subunit gamma P49368 CCT3 Cytosol 208 22/31 39 1.6 0.029 <0.05
19 T-complex protein 1 subunit epsilon P48643 CCT5 Cytosol 325 49/83 75 1.3 0.0001 <0.005
81 T-complex protein 1 subunit epsilon P48643 CCT5 Cytosol 250 39/81 70 1.8 0.014 <0.04
20 T-complex protein 1 subunit alpha P17987 TCP1 Cytosol 188 20/35 47 1.8 0.006 <0.03
77 T-complex protein 1 subunit alpha P17987 TCP1 Cytosol 268 25/40 54 −2.4 0.005 <0.03
21 T-complex protein 1 subunit zeta P40227 CCT6A Cytosol 155 27/93 48 1.7 0.034 <0.05
38 T-complex protein 1 subunit beta P78371 CCT2 Cytosol 152 17/34 35 −2 0.028 <0.05
95 T-complex protein 1 subunit beta P78371 CCT2 Cytosol 350 43/89 81 −2.2 0.031 <0.05
89 T-complex protein 1 subunit eta Q99832 CCT7 Cytosol 271 36/75 67 1.6 0.032 <0.05
60 LDLR chaperone MESD Q14696 MESDC2 Endoplasm
reticulum
74 7/21 32 −1.5 0.029 <0.05
22 60 kDa heat shock protein, mitochondrial P10809 HSPD1 Mitochondrion 170 23/49 51 2 0.007 <0.04
35 Stress-induced-phosphoprotein 1 P31948 STIP1 Cytosol/nucleus 177 32/86 51 −1.9 0.033 <0.05
67 Stress-induced-phosphoprotein 1 P31948 STIP1 Cytosol/nucleus 129 13/21 27 −7.6 0.0005 <0.01
69 Peptidyl-prolyl cis-trans isomerase B P23284 PPIB Endoplasm. reticulum 154 21/68 51 −1.4 0.0005 <0.01
Metabolism
Glucose metabolism
43 Pyruvate kinase isozymes M1/M2
(N-fragment)
P14618 PKM Cytosol 309 30/46 46 −2 0.021 <0.05
58 Pyruvate kinase isozymes M1/M2
(N-fragment)
P14618 PKM Cytosol 116 13/31 31 −2.3 0.027 <0.05
80 Pyruvate kinase isozymes M1/M2 P14618 PKM Cytosol 130 23/95 43 −2.4 0.008 <0.05
44 Glyceraldehyde-3-phosphate dehydrogenase P04406 GAPDH Cytosol 91 13/54 33 −1.6 0.028 <0.05
59 Glyceraldehyde-3-phosphate dehydrogenase P04406 GAPDH Cytosol 86 13/51 41 −1.7 0.038 <0.05
66 Glyceraldehyde-3-phosphate dehydrogenase P04406 GAPDH Cytosol 157 27/87 68 −6.2 0.005 <0.03
68 Alpha-enolase P06733 ENO1 Cytosol 289 31/62 70 −2.3 0.0002 <0.005
83 Phosphoglycerate kinase 1 P00558 PGK1 Cytosol 100 15/59 42 −1.5 0.024 <0.05
Galactose metabolism
40 Galactokinase P51570 GALK1 Cytosol 338 29/61 71 −1.7 0.037 <0.05
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Retinol metabolism
29 Retinal dehydrogenase 1 P00352 ALDH1A1 Cytosol 131 17/55 41 −1.5 0.038 <0.05
Cellular respiration and ATP metabolism
11 NADH-ubiquinone oxidoreductase 75 kDa subunit,
mitochondrial
P28331 NDUFS1 Mitochondrion 362 51/90 59 1.7 0.035 <0.05
63 ATP synthase subunit alpha, mitochondrial P25705 ATP5A1 Mitochondrion 158 22/48 36 −3.6 0.025 <0.05
91 Dihydrolipoyl dehydrogenase, mitochondrial P09622 DLD Mitochondrion 167 21/47 45 1.5 0.040 <0.05
Lipid metabolism
47 Isocitrate dehydrogenase O75874 IDH1 Cytosol/peroxis 172 20/55 48 −2.5 0.039 <0.05
55 Enoyl-CoA hydratase, mitochondrial P30084 ECHS1 Mitochondrion 160 22/65 50 −1.8 0.036 <0.05
Ketone metabolism
70 Succinyl-CoA: 3-ketoacid coenzyme A transferase
1, mitochondrial
P55809 OXCT1 Mitochondrion 154 17/36 45 −5.9 0.00007 <0.01
Amino-acid and protein metabolism
25 D-3-phosphoglycerate dehydrogenase O43175 PHGDH Cytosol 192 24/59 43 −3.9 0.037 <0.05
27 Cytosol aminopeptidase P28838 LAP3 Cytosol 169 21/63 50 −4.4 0.013 <0.04
Purine metabolism
65 Bifunctional purine biosynthesis protein PURH P31939 ATIC Mitochondrion 379 40/78 73 −2.6 0.0003 <0.01
4 C-1-tetrahydrofolate synthase, cytoplasmic P11586 MTHFD1 Cytosol 127 21/60 23 2.3 0.011 <0.04
88 GMP synthase [glutamine-hydrolyzing] P49915 GMPS Cytosol 340 39/77 57 −1.6 0.030 <0.05
74 GMP synthase [glutamine-hydrolyzing] P49915 GMPS Cytosol 338 29/35 48 1.8 0.002 <0.02
Transport
9 Mitochondrial inner membrane protein Q16891 IMMT Mitochondrion 178 17/25 27 −1.4 0.035 <0.05
84 Mitochondrial inner membrane protein Q16891 IMMT Mitochondrion 250 36/90 42 −1.5 0.003 <0.02
57 Protein SCO2 homolog, mitochondrial O43819 SCO2 Mitochondrion 105 12/69 55 −1.7 0.032 <0.05
49 Voltage-dependent anion-selective channel protein 2 P45880 VDAC2 Mitochondrion 110 13/73 64 −1.4 0.020 <0.05
Protein synthesis
6 Elongation factor 2 P13639 EEF2 Cytosol 331 35/47 49 2.9 0.034 <0.05
33 Elongation factor 2 P13639 EEF2 Cytosol 218 32/67 40 −2 0.030 <0.05
53 Elongation factor 2 P13639 EEF2 Cytosol 107 22/67 25 −2.3 0.010 <0.04
36 Elongation factor Tu, mitochondrial P49411 TUFM Mitochondrion 224 27/79 65 1.6 0.022 <0.05
16 Cleavage stimulation factor subunit 2 P33240 CSTF2 Nucleus 170 16/21 31 −1.4 0.039 <0.05
79 Far upstream element-binding protein 2 Q92945 KHSRP Nucleus 250 23/38 40 −2.8 0.008 <0.04
23 Far upstream element-binding protein 3 Q96I24 FUBP3 Nucleus 208 18/33 49 −1.8 0.037 <0.05
24 Far upstream element-binding protein 3 Q96I24 FUBP3 Nucleus 282 27/38 53 −1.6 0.039 <0.05
28 Pre-mRNA-processing factor 19 Q9UMS4 PRPF19 Nucleus 106 15/53 37 1.7 0.017 <0.05
30 Mitochondrial-processing peptidase subunit alpha Q10713 PMPCA Mitochondrion 93 16/69 33 −1.4 0.038 <0.05
45 Serine/arginine-rich splicing factor 1 Q07955 SRSF1 Nucleus 123 13/47 47 −2.3 0.036 <0.05
42 Heterogeneous nuclear ribonucleoprotein A/B Q99729 HNRNPAB Nucleus 134 15/38 31 −2.1 0.026 <0.05
17 Heterogeneous nuclear ribonucleoprotein Q O60506 SYNCRIP Nucleus 282 26/41 43 2.2 0.0007 <0.01
92 Heterogeneous nuclear ribonucleoprotein K P61978 HNRNPKH Nucleus 118 16/54 42 1.8 0.040 <0.05
62 Heterogeneous nuclear ribonucleoprotein H
(N-fragment)
P31943 HNRNPH1 Nucleus 110 15/46 36 −1.9 0.023 <0.05
(continued on next page)
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Table 2 (continued)
Spot
no. a
Protein description ACb Gene
name
Subcellular
localization
Mascot search results Fold change f
(Aubipyc vs
Control)
ANOVA
p-valueg
q-valueh
Score c Matched
Pept. d
Seq.
coverage
(%) e
82 Heterogeneous nuclear ribonucleoprotein H P31943 HNRNPH1 Nucleus 160 17/36 42 2.1 0.022 <0.05
64 Calreticulin (N-fragment) P27797 CALR Endo. reticulum 82 8/21 15 −1.7 0.020 <0.05
90 Eukaryotic translation initiation factor 4H Q15056 EIF4H Cytosol 147 17/54 57 −1.9 0.034 <0.05
Cell cycle and apoptosis
7 Programmed cell death 6-interacting protein Q8WUM4 PDCD6IP Cytosol 208 17/18 17 2.3 0.031 <0.05
41 Anamorsin Q6FI81 CIAPIN1 Cytosol/nucleus 169 18/72 61 −1.7 0.035 <0.05
31 Proliferation-associated protein 2G4 Q9UQ80 PA2G4 Cytosol/nucleus 182 26/54 54 −2.7 0.010 <0.04
52 Prohibitin P35232 PHB Mitochondrion 58 8/64 39 −2 0.023 <0.05
Cell redox homeostasis
26 Thioredoxin reductase 1, cytoplasmic Q16881 TXNRD1 Cytosol 62 12/65 27 −1.2 0.040 <0.05
32 Glutathione synthetase P48637 GSS Cytosol 212 24/61 54 1.4 0.028 <0.05
48 Peroxiredoxin-6 P30041 PRDX6 Cytosol 248 22/67 83 −4.6 0.040 <0.05
54 Peroxiredoxin-6 P30041 PRDX6 Cytosol 103 10/46 52 −1.7 0.040 <0.05
76 3-mercaptopyruvate sulfurtransferase P25325 MPST Mitochondrion 167 20/81 69 −1.6 0.002 <0.02
50 Protein disulfide-isomerase A3 (C-fragment) P30101 PDIA3 Endoplasm. reticulum 105 18/63 31 −2.8 0.025 <0.05
73 Protein disulfide-isomerase A3 P30101 PDIA3 Endoplasm. reticulum 182 26/90 48 −1.6 0.018 <0.05
Signal transduction
61 Heme-binding protein 1 Q9NRV9 HEBP1 Mitochondrion 200 21/55 90 −2.2 0.008 <0.04
51 Ankyrin repeat domain-containing
protein 42
Q8N9B4 ANKRD42 Nucleus 62 7/28 23 −3.5 0.008 <0.04
Cytoskeleton and cell structure
1 Vinculin P18206 VCL Cytoskeleton 283 29/37 32 1.8 0.006 <0.03
71 Vinculin P18206 VCL Cytoskeleton 363 50/82 45 −3.9 0.0001 <0.005
34 Actin-related protein 3 P61158 ACTR3 Cytoskeleton 219 25/64 61 1.6 0.008 <0.04
75 Protein enabled homolog Q8N8S7 ENAH Cytoskeleton 183 18/29 28 −2.7 0.002 <0.02
78 Ezrin P15311 EZR Cytoskeleton 278 35/58 49 2 0.008 <0.04
DNA replication and repair
85 RuvB-like 1 Q9Y265 RUVBL1 Nucleus 269 30/63 61 1.7 0.028 <0.05
93 Single-stranded DNA-binding protein, mitochondrial Q04837 SSBP1 Mitochondrion 117 13/42 62 1.2 0.040 <0.05
a Spot numbers match those reported in the representative 2-DE images shown in Fig. 2 (panels A and B).
b Accession number in Swiss-Prot/UniprotKB.
c MASCOT MS score (Matrix Science, London, UK; http://www.matrixscience.com). MS matching score greater than 56 was required for a significant MS hit (p-value < 0.05).
d Number of matched peptides correspond to peptide masses matching the top hit from Ms-Fit PMF, searched peptide are also reported.
e Sequence coverage = (number of the identified residues / total number of amino acid residues in the protein sequence) × 100%.
f Fold change (Aubipyc-treated cells vs control cells) was calculated dividing the average of %VAubipyc by the average of %Vcontrol. (V = volume = integration of the optical density over the spot area;
%V = V single spot/V total spots included in the reference gel) using Progenesis SameSpots 4.0 software.
g Anova test was performed by Progenesis SameSpots 4.0 software to determine if the relative change was statistically significant (p < 0.05).
h The q-value is a False Discovery Rate adjusted p-value (FDR) and it was calculated by the Progenesis SameSpots 4.0 software in order to establish how many of the significant ANOVA p-values were
false positives. Only the protein spots with a q-value < 0.05 were considered for the mass spectrometry analysis.
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Fig. 3 – Functional classification of differentially expressed
protein spots. The identified protein spots were sorted into
functional categories on the basis of the Gene Ontology (GO)
terms related to their major biological functions using
UniprotKB database (http://www.uniprot.org/). In the
histogram is reported the percentage of the up-regulated
proteins (black bars) and down-regulated proteins (white
bars) allocated in each functional category.
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mined and the values were statistically analyzed by two-tailed
non-paired Student-t-test. The resulting mean values ±SD, of
three independent experiments, were reported in the bar graph
in Fig. 6B. We found that the amount of these glycolytic
enzymes was statistically decreased in Aubipyc treated cells
with respect to controls (p-value < 0.05). The overall results
confirmed both the proteomic data and the pathway enrich-
ment analysis. It must be said, however, that GAPDH and PKM
Western blot results were not completely in line with those of
2-DE. In GAPDH blot, we detected only the band of 36 kDa
corresponding to full length protein (spot) whereas the bands of
35 kDa (spot 44) and 24 kDa (spot 59) were not detected by
anti-GAPDH antibody. In PKM blot, we detected the band of
57 kDa corresponding to full length protein (spot 80) and the
band of 36 kDa (spot 43) identified by mass spectrometry as
fragment. The band of 24 kDa (spot 43) was not revealed in this
blot. This discrepancy, between proteomic data and Western
blot, could be due to the lower amount of these undetected
bands or to the lack in the protein fragments of epitopes
recognizedby antibodies. There is some solid evidence that gold
based drugs mainly act through modification of selected
proteins (‘proteinmetalation’) with consequent loss of function
and destruction [48,49]. Therefore, to evaluate if, in our study,
the decreased amount of these enzymes was due to an
increased degradation, we performed theWestern blot analysis
onA2780 cells treated also for 48 h. The results at this timewere
similar to that at 24 h (Fig. S1). Indeed, for all the validated
enzymes, the amount of the relative full length protein wasstatistically lower in gold treated cells with respect to
controls (p-value < 0.05) but we did not observe a concomi-
tant appearance of protein fragments. Since the proteomics
and the Western blots allow to detect only stable protein
fragments, these results did not clarify whether the decrease in
the amount of these proteins is due to increased degradation or
decreased synthesis. Additional experiments are needed.
3.5. Metabolic investigations
Proteomic and bioinformatic results suggested a possible
cytotoxic effect of Aubipyc, directly or indirectly, on glycolysis
pathway. To investigate this hypothesis, we decided to perform
two additional experiments: i) the measure of the decrease in
glucose level in the culture medium and ii) the assessment of
the effect of extra pyruvate addition in the culture medium on
antiproliferative activity of Aubipyc against A2780/S cells.
Concerning the glucose assay, we cultured the treated and
untreated A2780/S cells for 48 h. Glucose concentration was
measured in 1 mL of medium supernatant harvested immedi-
ately after the addition of 3.1 μMAubipyc (time 0) and then after
6, 12, 24, and 48 h. Experiments were performed in triplicate.
The resulting mean values ± SD were reported in the bar graph
in Fig. 7.We found that at both 24 and 48 h the glucose levelwas
statistically higher in Aubipyc treated cells with respect to
controls (p-value < 0.05 by two-tailed non-paired Student's-t-
test). In treated cellswemeasureda glucose amountof 1.3 times
higher at 24 h and 2 times higher at 48 h than in control cells.
Thus, this result showed that Aubipyc treated cells consume
less glucose than controls. Concerning the addition of extra
pyruvate in the culturemedium,we observed that it induced an
increase of the IC50 drug concentration value (Table 3). As
reported in Section 3.1 and in Table 1, after 72 h of exposure to
Aubipyc, the IC50 value was 3.1 μM. In the presence of 1 mM of
pyruvate, the IC50 value turned out to be 8.4 μMat 72 h (Table 3).
This finding suggested that the addition of pyruvate attenuated
the gold cytotoxic effect.
3.6. Network analysis
To better understand the key regulated biological processes
occurring in A2780/S cell line after Aubipyc treatment,
bioinformatics analysis to the list of identified proteins was
carried out. The network analysis used is the web-based tool
for the interpretation of experimentally derived protein lists
in the context of a global PPI network PPI Spider [38,50]. We
put in the same analysis all the identified proteins listed in
Table 2. To start the analysis, we uploaded all these identified
proteins, corresponding to 63 unique proteins and we selected
H. sapiens as organism. In Fig. 8 (obtained by Cytoscape: http://
www.cytoscape.org/) there is a reported graphical illustration
of the protein–protein interaction network created by the
analysis. The table reported in Fig. 8 summarizes the results
for this submission using the PPI Spider tool. In the table, the
models' definition is also shown which specifies the maximal
allowed distance between two input proteins connected (D1
means directly connected, D2 one intermediate is allowed),
the number of input proteins covered by the system, and the
corresponding significance of the best inferred model. Model
D1 (p-value < 0.005) covers 8 proteins of the 63 submitted to the
Fig. 4 – Functional GO Biological Process (BP) terms enrichment. GO BP terms statistically over-represented by the up-regulated
(A) and the down-regulated (B) protein spots were achieved using the web-accessible program Database Annotation
Visualization and Integrated Discovery version 6.7 (DAVID, http://david.abcc.ncifcrf.gov/home.jsp). The values in brackets are
the p-values after Benjamini correction of each BP term. Detailed composition and statistical parameters of these GO terms
were reported in Table S2.
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they include 6 subunits of T-complex protein 1 family, the
mitochondrial innermembrane protein (IMMT, Q16891) and the
cleavage stimulation factor subunit 2 (CSTF2, P33240). The
inferred network model D2 (p-value < 0.005) includes 45 of the
identified proteins and 31 new proteins representing common
interactors able to connectmost of the proteins in the input list.
These 31 intermediate nodes are represented as triangles in the
network of Fig. 8. We focused on proteins which represent the
main nodes of this network. The interconnected proteins in the
network D1 are linked to the network D2 by the intermediate
node RAF1. It is a serine/threonine–protein kinase that acts as a
regulatory link between themembrane-associated Ras GTPases
and theMAPK/ERK cascade, thus playing an important role in
the control of gene expression involved in the cell division
cycle, apoptosis, cell differentiation, and cell migration. In
the network D2, HSP60 mitochondrial (P10809) represents a
central node. It interacts with 5 intermediates not identified
by the proteomic analysis (RAF1, SIRT1, SIRT3, PPP2R-1B, and
SPG20). The proteins SIRT1 and SIRT3 are deacetylases
belonging to the sirtuin family. Sirt1 participates in the
coordination of several functions such as cell cycle, responseto DNA damage, metabolism, apoptosis and autophagy.
SIRT3 is a NAD-dependent protein deacetylase which acti-
vates mitochondrial target proteins such as ACSS1, IDH2 and
GDH contributing to the regulation of the cellular energy
metabolism. In our network, Sirt3 is connected to the identified
mitochondrial subunit alpha of ATP synthase (P25705). The
central node HSP60 also interacts with the protein PPP2R-1B
that belongs to the phosphatase 2A regulatory subunit A family
involved in the positive regulation of extrinsic apoptotic
signaling pathway. Among the intermediate nodes connected
to PPP2R-1B, we found proteins that function in folding,
transcription regulation, cell cycle regulation and energy
metabolism. We also found two intermediates involved in
signal transduction such as MAPK13 and MAP3K3. MAPK13 is
one of the four p38 MAPKs which plays an important role in the
cellular responses to proinflammatory cytokines or physical
stress leading to direct activation of transcription factors such
as ELK1 and ATF2. Moreover it mediates activation of the
NF-kappa-B, AP1 and DDIT3 transcriptional regulators REF.
Concerning SPG20 (spartin), the last intermediate node inter-
connected to HSP60 mitochondrial, it is involved in many
cellular processes and associates with several intracellular
Fig. 5 – Glycolysis pathway enrichment. (A) Biocarta and KEGG pathway results obtained using the down-regulated protein list.
The analysis was performed by DAVID and accepting a p-value <0.1 after Benjamini correction. (B) Graphical representation of
glycolysis pathway. The dashed areas denote the identified proteins involved in the glycolysis pathway enrichment.
115J O U R N A L O F P R O T E O M I C S 1 0 3 ( 2 0 1 4 ) 1 0 3 – 1 2 0organelles, including mitochondria [51]. This intermediate is
connected through the stress-70 proteinmitochondrial (P38646)
to the identified Calreticulin (P27797). This protein represents
another important node of the network D2. Calreticulin
interacts with four new intermediate nodes: TAP1, ELF3,
PAK2, and REL which play different biological roles. TAP1 has
a peptide transport activity whereas ELF3 is involved in
transcription regulation. PAK2, a serine/threonine protein
kinase, plays a role in: cytoskeleton regulation, cell motility,
cell cycle progression, apoptosis or proliferation. It acts as a
downstream effector of the small GTPases CDC42 and RAC1.
Interestingly, among the intermediate nodes connected to
PK2, we found two proteins (TAB1, RIPK2) that are involved in
the positive regulation of I-kappaB kinase/NF-kappaB cas-
cade. REL, the last interactor of Calreticulin, is involved in the
positive regulation of I-kappaB kinase/NF-kappaB cascade.
Among the intermediate nodes connected to REL, we found
few proteins related to cell growth, survival and apoptosis.Key proteins of this pathway, TOB1, DIDO1 and TRAF1,
regulate the sensitivity of cells to anti-proliferative and
apoptotic stimulus [52–54]. Moreover, REL is linked through
the identified glycolytic enzyme GAPDH (P04406), with the
intermediate node DHRS2 (dehydrogenase/reductase SDR
family member 2, mitochondrial) a mitochondrial protein
with a functional role in promoting growth inhibition. In
turn, this protein is linked to the identified mitochondrial
proteins Prohibitin (P35232) and voltage-dependent anion
channel 2 (VDAC2, P45880). Fusion and fission maintain the
functional integrity of mitochondria and Prohibitin forms
large ring complexes in the inner membrane. It inhibits DNA
synthesis and it has a role in regulating cell proliferation and
mitochondrial respiration activity [55]. The VDAC family of
proteins are considered as the main pathway for metabolite
diffusion across the mitochondrial outer membrane and are
involved in the BCL2mitochondrial apoptotic pathway. VDAC
and Prohibitin were found associated with an Alzheimer's
Fig. 6 – Validation of proteomic results by Western blot. Western blot was probed with antibodies against GAPDH, PGK1, ENO1
and PKM proteins identified by proteomic analysis. The intensity of immune-stained bands was normalized with the total
protein intensities measured from the same blot stained with Coomassie brilliant blue. (A) Representative Western blot image
of A2780/S cells treated for 24 h with Aubipyc concentration corresponding to its 72-h-exposure IC50 dose (3.1 μM). (B) In the
histogram, for each protein, the mean value ±SD of Western blot signals, expressed as arbitrary units (black bars: control cells;
white bars: Aubipyc-treated cells), is reported. For each protein, three biological replicates were performed. The two-tailed
non-paired Student's-t-test was carried out using Graphpad Prism 4. The amount of each protein was statistically different
between control and treated cells (p-value < 0.05).
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environment, induces a reversible mitochondrial phenotype
similar to that found in the disease [56].Fig. 7 – Glucose assay. A2780/S cells were treated for 48 h
with Aubipyc concentration corresponding to its
72-h-exposure IC50 dose (3.1 μM). Glucose level was
assessed in 1 mL of medium supernatant immediately after
the addition of Aubipyc (time 0) and after 6, 12, 24 and 48 h.
For each time point, three biological replicates were per-
formed. The two-tailed non-paired Student's-t-test was
carried out using Graphpad Prism 4. In the histogram, the
mean value ±SD of the glucose amount expressed as ng
glucose/cell number (black bars: control cells; white bars:
Aubipyc-treated cells) is reported. A p-value < 0.05 was
considered statistically significant (*).4. Discussions
The main goal of the present investigation was to examine the
cytotoxic effects and the associated proteomic alterations of the
representative gold compound namely Aubipyc on the A2780/S
cancer cell line in the attempt to delineate its likely mode of
action. We carried out a comparative proteomic study using
2-DE coupled with mass spectrometry. The results pointed out
95 differentially expressed protein spots following Aubipyc
treatment. We successfully identified 87 of these protein spots
and among them, in treated cells, 29 resulted up-regulated and
58 down-regulated. These proteins play specific roles in a
variety of biological processes. Most of them belong to
functional classes i.e. stress response and chaperones, protein
synthesis, metabolism and cell redox homeostasis and cyto-
skeleton and cell structure.
In order to understand the biological meaning behind the
list of identified proteins, we analyzed separately the up- and
down-regulated proteins by the web-accessible program
DAVID. This program provides information about the GO
terms enriched by a dataset of proteins or genes. Processing
the up-regulated proteins we found statistically enriched GOTable 3 – Effect of extra pyruvate addition in the culture
medium on antiproliferative activity of Aubipyc against
A2780/S cell line.
Compound A2780/S IC50 [μM] ± SE p-value
No extra pyruvate +1 mM pyruvate
Aubipyc 3.1 ± 0.1 8.4 ± 0.4 0.0017
n 3 3
n, number of experiments; SE, standard error.
Fig. 8 – PPI Spider results by Bioprofiling.de. The network represents the interactome in which all the identified proteins are
involved.
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process’. Most of the proteins involved in this enrichment
belong to the functional class ‘stress response and chaper-
ones’. We found several subunits of T-complex protein 1
(CCT3, CCT5, TCP1, CCT6A, CCT7) and different members of
the heat shock family such as HSP60mitochondrial, Stress-70
protein mitochondrial and heat shock 70 kDa protein 4L and
heat shock cognate 71 kDa protein. Several studies reported an
increase of Hsp expression upon exposure to anticancer agents.
These chaperones may participate in the stress response to
drug-induced damage [57]. Experimental evidence supports the
dual capability of anticancer drugs to act as lethal agents for
tumor cells as well as to induce the adaptive stress response in
the neoplastic environment. Anticancer drugs activate cell
death programs [58] and modulate expression of genes that
are essential for drug resistance [59]. In fact, in addition to their
normal housekeeping character in folding proteins, the fre-
quently protective induction of HSPs in response to stress and
their role in the regulation of death signals are well recognized
[60]. The HSPs are implicated in both the effectiveness and the
tolerance to chemotherapy [60]. T-complex protein 1 subunits
were already found to be involved in the process of cisplatin
resistance by Castagna et al. [61]. It is noteworthy that some of
these chaperones, such as TCP1, heat shock 70 kDa protein 4L
and heat shock cognate 71 kDa protein, resulted both increase
and decrease in protein abundance. This apparent discrepancy
occurred because we found a decrease in the amount of spotscorresponding to the full length protein with a concomitant
increase in the amount of protein spots with a lower Mr. This
may be explain with the presence of protein fragmentation due
to gold treatment or with the presence of different protein
species.
Analyzing the down- regulated proteins list, we statistically
enriched GO BP terms associated with metabolism and energy
production (‘metabolic process’, ‘generation of precursor me-
tabolites and energy’, and ‘glycolysis’). Most of the proteins
involved in this enrichment aremetabolic enzymes such as the
glycolytic enzymes PKM, GAPDH, ENO1, and PGK1. We also
found enzymes of different metabolic processes such as ATP
metabolism, galactose metabolism, retinol metabolism, lipid
and ketone metabolism, amino-acid and protein metabolism.
Another GO BP term enriched within the list of down-regulated
proteins was ‘cell redox homeostasis’. The mitochondrial SCO2
homolog, peroxiredoxin-6, protein disulfide-isomerase A3 and
the cytoplasmic thioredoxin reductase 1 were clustered in this
enrichment. An interesting finding of this functional analysis
dealt with the enrichment of GO terms associated with glucose
metabolism. In linewith this result, the down-regulated protein
also statistically enriched the pathway ‘glycolysis’. This data
was also confirmed byWestern blot analysis in which the level
of the glycolytic enzymes PKM, GAPDH, ENO1, and PGK1 were
decreased after Aubipyc treatment. Genes of glucose metabo-
lism have been reported to be ubiquitously over-expressed in
cancer cells [62]. Many researchers have shown that tumors
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cells compensates for mitochondrial dysfunction and also
provides resistance to apoptosis. Moreover, these metabolic
alterations are responsible for chemoresistance in cancer
therapy. Glyceraldehyde-3-phosphate dehydrogenase and
alpha enolase seem to be relevant in the acquisition of drug
resistance in cancer cell lines, due to their transcriptional
regulation activity more than their function in glycolysis [63].
Therefore, the combination of anticancer chemotherapeutics
and metabolic modulators could be a promising strategy to
overcome chemoresistance [64]. Moreover, we found mark-
edly decreased the amount of an isocitrate dehydrogenase
isoform upon Aubipyc treatment. Its role in chemoresistance
still remains to be elucidated, however it was already found
to be involved in drug resistance in ovarian and other types of
cancer [65,66].
In conclusion the proteomic and bioinformatic results
underline a potential negative effect of Aubipyc treatment on
glucosemetabolism that might lead to the activation of a stress
responsemediated by chaperones and stress response proteins.
We also supported this hypothesis by the assessment of the
glucose level in the culture medium after gold treatment. The
results revealed that after 24 and 48 h, A2780/S treated cells
displayed a higher amount of glucose with respect to controls
indicating a lower consumption of this sugar. Moreover, the
antiproliferative activity of Aubipycwas reduced by the addition
of extra pyruvate in the culture medium. This indicates that
pyruvate can overcome the slowdown of glycolytic flux and
confirms that Aubipyc acts, at least as a part of itsmechanismof
action, affecting glycolytic pathway.
The variations in protein expressions pointed out by our
proteomic analysis could be an indirect consequence of other
changes affecting less expressed and non detectable pro-
teins. To identify these proteins we performed a pathway
analysis using the global PPI Spider network. The network
includes 45 of the 87 proteins identified in this study and 31
new intermediate proteins, whose expression level could be
influenced by the Aubipyc treatment. Several identified
proteins belong to the functional class ‘chaperones and
stress response’ such as the central node of the network
HSP60 mitochondrial, HSP90AB1, stress-70 mitochondrial
protein, HSP704L and STIP1. We found new interactors
involved in transcription regulation and mRNA splicing
such as EIF2C3, TFES, ELF3, HMGA1 and PUF60. These findings
agree with the GO functional analysis supporting an involve-
ment of the biological process ‘protein folding’ and ‘protein
synthesis’ in Aubipyc cytotoxicity response. It is worthwhile to
note thatmost of the 31new intermediate nodes are involved in
the functional classes ‘cell cycle and apoptosis’, and ‘DNA
replication and repair’. Among the proteins implicated in the
apoptotic process, we found RAF1, SIRT1, PPP2R-1B, PAK2, REL,
TRAF1, TOB1, DIDO1, Prohibitin, PDCD6IP (Q8WUM4) and
VADAC2 [67,68]. This datum strongly correlates to the recent
studies on the mechanisms through which Aubipyc causes cell
death. Indeed, it was found that this gold compound induces
extensive apoptotic cell death [21]. Due to the fact that Aubipyc
is a strong inhibitor of mitochondrial thioredoxin reductase
[23], it was proposed that apoptotic cell death might arise
from direct mitochondrial damage. In line with this hypoth-
esis, we found several proteins related to the mitochondrialfunctionality such as the NAD+-dependent deacetylase
SIRT3 [69], Prohibitin, VADC2 and DHRS2. Interestingly, we
found proteins associated with the GO biological process
‘I-kappaB kinase/NF-kappaB cascade’ such as REL, TRAF1,
MAP3K3, RIPK2and TAB1. This pathway has been associated
to other metallo-drugs. It has been shown that, in cervical
carcinoma cells, cisplatin treatment-induced NF-kappaB
down-regulation is mediated by TRAF2, and it triggers the
membrane death receptor/mitochondria-mediated apoptotic
pathway [25]. Furthermore, the activation of nuclear factor
kappaB (NF-kappaB) contributes to drug resistance in pancre-
atic carcinoma and it was demonstrated that pretreatment of
pancreatic carcinoma cells with genistein, that down-regulates
NF-kappaB activity, enhances the apoptosis-inducing effect of
cisplatin, leading to greater antitumor activity in vivo [70].
Moreover, anti-rheumatic gold compounds, such as auranofin,
have been shown to inhibit NF-κB activation by blocking IκB
kinase (IKK) activity.
In conclusion the network analysis highlighted the in-
volvement of proteins associated with biological processes, as
protein folding and synthesis, apoptosis and cellular prolifer-
ation, in response to Aubipyc exposure, thus supporting the
proteomic results. Moreover, this analysis led to the identifi-
cation of proteins associated with NF-kB pathway. Some of
these proteins may be further investigated to better identify
and characterize the cellular perturbations induced by
Aubipyc.5. Conclusions
In summary, we have reported here the first proteomic
analysis regarding Aubipyc cytotoxicity on A2780/S cell line.
The proteomic study revealed for Aubipyc different cellular
alterations with respect to cisplatin as well as to other gold
compound such as auranofin. Remarkably, from our bioin-
formatic and functional analysis, it emerged quite clearly
that Aubipyc treatment affected, directly or indirectly, several
glycolytic enzymes leading to a possible down-regulation of
glucose metabolism. However, it should be kept in mind that
this work is just a first exploration of the mechanisms
underlying the cytotoxic effects of Aubipyc. Further study is
actually required to clarify the specific role exerted by the
identified proteins and their corresponding pathways in cell
response to drug-induced damage. Additional analyses are
needed to demonstrate if Aubipyc is able to bind directly
these proteins or at least some of them. At present, we are
performing a parallel proteomic study on the A2780/R cell
line in order to verify if Aubipyc treatment is able to affect the
expression level of proteins associated to cisplatin resis-
tance. This study might further confirm the mechanistic
results achieved with the present investigation.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jprot.2014.03.032.Transparency Document
The Transparency document associated with this article can
be found, in the online version.
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